Intertek opens bioanalysis plant in UK to support biosimilar growth

By Dan Stanton contact

- Last updated on GMT

Intertek opens bioanalysis plant in UK to support biosimilar growth

Related tags: Immune system

Intertek has added 10,000 ft² of bioanalytical laboratory space through a new UK facility, the second to be opened this year.

In May​, Intertek opened a stability testing facility for small molecules and biologics in Royston, near Cambridge, UK, and today the contract services firm has announced its10,000 ft² bioanalytical and biopharmaceutical characterisation facility is now open for business in Manchester.

The site will offer drug companies bioanalysis, immunogenicity and characterisation services for monoclonal antibodies (mAbs), recombinant proteins and vaccines, and will operate as part of Intertek’s Centre of Excellence for Biologics.

“This investment is key to providing the level of resource required to meet the ever increasing demand for our expertise and experience,”​ said Chetan Parmar, Intertek’s Senior Vice President.

“Among the exciting projects now starting at this lab is testing of novel monoclonal antibody therapeutics, as well as antibody drug conjugates, which are highly complex yet offer great potential for a range of difficult-to-treat cancers.”

The company says it is seeing a growing demand for contract safety and efficacy services for biologics, as well as comparability and characterization testing services for mAbs, driven in part by the growth in biosimilar development.

The expansion was announced earlier this year​, with a spokeswoman at the time telling this publication the lab mirrors the firm’s existing San Diego immunochemistry facility.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more